Over the past several months leading up to the November presidential and congressional elections, organizations representing urology sought to persuade members of Congress to bring sense and reason to the U.S. Preventive Services Task Force (USPSTF), which nearly 5 years ago gave a “D” rating to PSA-based screening for prostate cancer.
In this article, I outline what urologists should know about major provisions in the 2017 Medicare Physician Fee Schedule and how it may impact their bottom line.
Here is a list of potential estate-planning mistakes you can help avoid with professional counseling.
Percutaneous nephrolithotomy in the presence of aspirin appears both effective and safe. In a retrospective review of almost 300 PCNL cases, postoperative hemorrhage was uncommon in patients who continued aspirin preoperatively, said Brandon Otto, MD, at the AUA annual meeting in San Diego.
Findings from an initial cost analysis support further research and reconsideration of the role of computed tomography urography for imaging evaluation in patients with asymptomatic microhematuria, according to urologists from the University of Alabama at Birmingham.
Fewer than 20% of patients with biochemical recurrence after radical prostatectomy develop metastasis, and a smaller proportion die as a result of prostate cancer.
Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
In this interview, Khurshid R. Ghani, MD, and David C. Miller, MD, MPH, discuss the origins of the Michigan Urological Surgery Improvement Collaborative, what it’s done for prostate cancer care in Michigan, and how a similar model could be rolled out nationally.
"There are significant data examining the role of heat exposure to male sperm. However, none of it is very high quality and the data are murky at best," write James R. Craig, MD, MS; William Brant, MD; and James M. Hotaling, MD, MS.
In the 2016 elections, a urologist was elected to the House of Representatives but overall physician representation in Congress has declined to just 3%.
“Our research shows that the implications of kidney stones may go beyond the discomfort they are so often associated with,” says co-lead author Andrew Rule, MD.
A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
UT blogger Lisa Kerr, PA-C, makes her case for using physician assistants to first assist on surgical procedures.
Urologist Henry Rosevear, MD, discusses a recent OR experience that had him rethink his value as a surgeon and consider a possible alternative to better align the financial incentives of the surgeon with the hospital's goals.
Urology resident, Amy Pearlman, MD, discusses how the experience of helping her mother go through radiation therapy changed how she is able to relate to her patients.
Testosterone replacement therapy may not have the benefit many physicians think it does-particularly for women grappling with sexual dysfunction.
Urology Times conducted a survey in June and July 2016 in which we sought urologists’ opinions on maintenance of certification. These charts provide a snapshot of their thoughts regarding the controversial program.
Ureteral reimplantation videos.
. Prescribers should know that the FDA has updated its warnings to say that fluoroquinolones should not be prescribed to patients who have other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections
Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
The genomic profiling tool distinguishes among the dominant three malignant and one benign renal cancer subtypes.
Two late-stage immunotherapy drugs for the treatment of urothelial carcinoma reach regulatory, research milestones.
In this exclusive interview, Andy Slavitt, acting administrator for the Centers for Medicare & Medicaid Services, discusses alternative payment models, outlines what resources are available for practices, and provides an overview of the three options practices have for participation in the Quality Payment Program.
Testosterone therapy in hypogonadal men with prostate cancer who have had definitive treatment and in those on surveillance appears to be safe, according to a new study.
An examination of data involving more than 63,000 PSA tests ordered by primary care physicians reveals some surprising findings.